Pegylated liposomal doxorubicin in treating a case of advanced hepatocellular carcinoma with severe hepatic dysfunction and pharmacokinetic study
Open Access
- 1 March 2000
- journal article
- case report
- Published by Elsevier in Annals of Oncology
- Vol. 11 (3) , 349-354
- https://doi.org/10.1023/a:1008394125040
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma modelInternational Journal of Cancer, 1999
- Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patientsBritish Journal of Cancer, 1998
- Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.Journal of Clinical Oncology, 1997
- Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group studyInvestigational New Drugs, 1997
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.Journal of Clinical Oncology, 1997
- Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trialsAnnals of Oncology, 1997
- Intra-Hepatic Arterial Drug DeliveryJournal of Drug Targeting, 1996
- Recent advances in liposomal drug-delivery systemsCurrent Opinion in Biotechnology, 1995
- Long-circulating (sterically stabilized) liposomes for targeted drug deliveryTrends in Pharmacological Sciences, 1994
- Sterically stabilized liposomesBiochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, 1992